Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Pollen power? new study tests natural remedy for hot flashes

NCT ID NCT06889753

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This study tests whether pollen extracts can reduce menopause symptoms like hot flashes and night sweats in healthy women aged 45-60. Over 36 weeks, 120 participants will take either a water-soluble pollen extract, a lipid-soluble pollen extract, or a placebo pill. Researchers will measure changes in symptom severity using a standard rating scale.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pollen extracts (water-soluble and lipid-soluble)
What this could lead to
If it works, this could offer a natural option to reduce menopause symptoms like hot flashes and night sweats.
What could go wrong
This is an early phase 2 trial with only 120 women, so results may not apply to everyone. Dietary supplements often show limited effects compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 65 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Females between 45-60 years of age, inclusive 2. BMI 18.5 kg/m2 - 34.9 kg/m2 inclusive 3. Self-reported menopausal women who have not had a menstrual period for \>12 months prior to screening and are experiencing at least moderate menopausal symptoms as assessed by the total MRS score of ≥9 at screening 4. Presence of menopausal symptoms for at least six months prior to screening including, vasomotor symptoms (hot flushes, sweating) AND at least two of the following symptoms: sleep disturbance, joint pain, mood changes, fatigue and lack of energy, vaginal dryness, urinary changes, and changes in sexual function 5. Agrees to maintain current lifestyle as much as possible throughout the study, including diet, exercise, medications, dietary supplements, and sleep 6. Able and willing to complete all study assessments 7. Provided voluntary, written, informed consent to participate in the study 8. Healthy as determined by medical history with no unstable, diagnosed medical conditions as assessed by the Qualified Investigator (QI) Exclusion Criteria: 1. Females who have had unilateral oophorectomy or hysterectomy or uterine ablation 2. Allergy (including bee products or pollen, sensitivity, or intolerance to investigational products or placebo ingredients 3. Ongoing diagnosis with anxiety disorder, sleep disorder, or major depression as assessed by the QI 4. Ongoing unstable diagnosis of musculoskeletal disorders as assessed by the QI 5. Current untreated urogenital diagnosis as assessed by the QI 6. Unstable metabolic disease or chronic diseases as assessed by the QI 7. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI 8. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI 9. Current unstable Type I or Type II diabetes 10. Significant cardiovascular event in the past six months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis 11. History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months 12. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least three months will be considered by the QI 13. Major surgery in the past three months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI 14. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years 15. after diagnosis are acceptable 16. Individuals with unstable autoimmune disease or are immune compromised as assessed by the QI 17. Use of medical cannabinoid products 18. Chronic use of cannabinoid products (\>2 times/week) as assessed by the QI 19. Alcohol intake average of \>2 standard drinks per day as assessed by the QI 20. Alcohol or drug abuse within the last 12 months 21. Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy of the investigational product (Sections 7.3.1 and 7.3.2) 22. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI 23. Individuals who are unable to give informed consent 24. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant 25. Asthmatic, as assessed by the QI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Menopausal women are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • KGK Science Inc.

    RECRUITING

    London, Ontario, N6B3L1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.